ライフサイエンスコーパス: growth factor receptor

1 ed in Dsg2 C-terminal fragment and epidermal growth factor receptor.

2 c-Src-mediated transactivation of epidermal growth factor receptor.

3 7)Lu-cetuximab), that acts as anti-epidermal growth factor receptor.

4 tokine TNFalpha and ligands of the epidermal growth factor receptor.

5 ulin receptor and/or the type 1 insulin-like growth factor receptor.

6 factor receptor, Ins-Ralpha, and fibroblast growth factor receptors.

7 ytosis can regulate the fate and activity of growth factor receptors.

8 of diseases caused by variants in Fibroblast Growth Factor Receptor 1 ( FGFR1) and report a novel, de

9 he receptor tyrosine kinases (RTK) epidermal growth factor receptor 1 (EGFR) and human epidermal grow

10 CRISPR/Cas9-mediated deletion of fibroblast growth factor receptor 1 (FGFR1) or pretreatment with in

11 ctor receptor alpha (PDGFRA), and fibroblast growth factor receptor 1 (FGFR1) to cell proliferation a

12 Here we show that transforming growth factor receptor 1 (TGFbetaR1) has an indispensabl

13 that the expression of vascular endothelial growth factor receptor 1 (VEGFR1) by pericytes spatially

14 sion and recruitment of vascular endothelial growth factor receptor 1 (VEGFR1)-expressing perivascula

15 denced by a decrease in vascular endothelial growth factor receptor 1 positive (VEGFR1(+)) myeloid ce

16 growth factor A and D; vascular endothelial growth factor receptor 1, 2, and 3; osteopontin; transfo

17 ctivity associated with vascular endothelial growth factor receptors 1, 2, and 3, currently in phase

18 Membrane-localized vascular endothelial growth factor receptor-1 (mVEGFR1) is an endothelial cel

19 CI, 2.46-5.87; P < .001) and human epidermal growth factor receptor 2 (ERBB2 [formerly HER2])-enriche

20 latory mechanism of one such RTK, fibroblast growth factor receptor 2 (FGFR2) kinase, is still unknow

21 to adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2) -positive early breast c

22 O was conjugated to the anti-human epidermal growth factor receptor 2 (HER2) Affibody molecule Z2395.

23 rowth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) and HER2/HER3 heterodime

24 s of the ErbB family, namely human epidermal growth factor receptor 2 (HER2) and human epidermal grow

25 simultaneously targeting the human epidermal growth factor receptor 2 (HER2) expressed by cancer cell

26 An example is human epidermal growth factor receptor 2 (HER2) overexpressing breast ca

27 expression and negative for human epidermal growth factor receptor 2 (HER2) overexpression.

28 e, tumors were classified as human epidermal growth factor receptor 2 (HER2) positive (n = 51), estro

29 pathologic classification of human epidermal growth factor receptor 2 (HER2) status in women with met

30 Human epidermal growth factor receptor 2 (HER2) status is one of the maj

31 ologists recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer

32 the extracellular domain of human epidermal growth factor receptor 2 (HER2), 3 other HER2-targeting

33 detection and estimation of human epidermal growth factor receptor 2 (HER2), a biomarker for breast

34 sensitive quantification of Human Epidermal growth factor Receptor 2 (HER2), as a key prognostic tum

35 sis of status with regard to human epidermal growth factor receptor 2 (HER2), hormone receptors, and

36 ased its activity toward the human epidermal growth factor receptor 2 (HER2)- pY(1196) site, but not

37 ors, 70.5% of luminal B-like human epidermal growth factor receptor 2 (HER2)-negative tumors, 82.8% o

38 s hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative

39 rmone receptor (HR)-negative human epidermal growth factor receptor 2 (HER2)-positive (1.1% among ent

40 gesterone receptor-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancer w

41 In human epidermal growth factor receptor 2 (HER2)-positive breast cancer,

42 therapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

43 djuvant targeted therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancers

44 djuvant trials, treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancers

45 ive-year BCSS was highest in human epidermal growth factor receptor 2 (HER2)-positive disease [95.8%;

46 al outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive esophagogastric

47 r treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic bre

48 Purpose Human epidermal growth factor receptor 2 (HER2)-positive/hormone recepto

49 (89)Zr-pertuzumab PET/CT for human epidermal growth factor receptor 2 (HER2)-targeted imaging in pati

50 ceptor (HR) and negative for human epidermal growth factor receptor 2 (HER2).

51 efficacy of chemotherapy and human epidermal growth factor receptor 2 (HER2, encoded by the gene ERBB

52 membrane antigen (n = 7) or human epidermal growth factor receptor 2 (n = 5).

53 Vascular endothelial growth factor receptor 2 (VEGFR2) localized on the surfa

54 by using clinical-grade vascular endothelial growth factor receptor 2 (VEGFR2)-targeted microbubbles

55 ancer (luminal A, luminal B, human epidermal growth factor receptor 2 [currently known as ERBB2, but

56 types: luminal A, luminal B, human epidermal growth factor receptor 2 enriched, and basal like.

57 based assay for detection of human epidermal growth factor receptor 2 protein (HER2) cancer biomarker

58 tric oxide synthase/Akt/vascular endothelial growth factor receptor 2 signaling, and a reduction in o

59 sed on estrogen receptor and human epidermal growth factor receptor 2 status was also assessed.

60 he number of lymph nodes and human epidermal growth factor receptor 2 status.

61 , progesterone receptor, and human epidermal growth factor receptor 2 was found to guide choices of s

62 on of anti-TLR2 and antivascular endothelial growth factor receptor 2 yielded an additive therapeutic

63 ) content, and HER2 content (human epidermal growth factor receptor 2).

64 ogesterone receptor+, and/or human epidermal growth factor receptor 2+ tumors.

65 le actin, CD31, phospho-vascular endothelial growth factor receptor 2, and p42/44 mitogen-activated p

66 solid body tumors (such as human epithelial growth factor receptor 2, breast cancer susceptibility p

67 ral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard

68 n estrogen receptor (ER) and human epidermal growth factor receptor 2, the androgen receptor (AR) is

69 n hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

70 S in patients with high-risk human epidermal growth factor receptor 2-negative breast cancer compared

71 Results For 240 human epidermal growth factor receptor 2-negative patients younger than

72 For 145 human epidermal growth factor receptor 2-negative patients younger than

73 y of trastuzumab therapy for human epidermal growth factor receptor 2-overexpressing (HER2-positive)

74 v 6%; P = .08), but not for human epidermal growth factor receptor 2-positive (luminal and nonlumina

75 re for adjuvant treatment of human epidermal growth factor receptor 2-positive breast cancer.

76 treatment of node-positive, human epidermal growth factor receptor 2-positive early-stage breast can

77 RT, although, in our study, human epidermal growth factor receptor 2-positive tumors seemed to be mo

78 was no amplification of the human epidermal growth factor receptor 2/ neu gene.

79 tric oxide synthase/Akt/vascular endothelial growth factor receptor 2/oxidative stress-inflammation-d

80 ial growth factors A/C, vascular endothelial growth factor receptors 2/3, angiopoietin 1/2, and angio

81 eptor are not expressed, and human epidermal growth factor-receptor 2 is not amplified or overexpress

82 criptional regulation of the human epidermal growth factor receptor-2 (HER2) contributes to an enhanc

83 ssing CD133, CXCR4, and vascular endothelial growth factor receptor-2 epitopes.

84 expressing CD34, CD133, vascular endothelial growth factor receptor-2, and chemokine (C-X-C motif) re

85 luding estrogen receptor and human epidermal growth factor receptor-2.

86 Fibroblast growth factor receptor 3 (FGFR3) coimmunoprecipitated wi

87 We recently found that the fibroblast growth factor receptor 3 (FGFR3) interacts with and medi

88 by a gain-of function mutation in fibroblast growth factor receptor 3 (FGFR3).

89 The human epidermal growth factor receptor 3 (HER3) is an interesting target

90 prominent expression of the human epidermal growth factor receptor 3 (HER3) on the cell surface.

91 factor receptor 1 (EGFR) and human epidermal growth factor receptor 3 (HER3), leading to persistent g

92 factor receptor 2 (HER2) and human epidermal growth factor receptor 3 (HER3), was examined.

93 onal antibodies against vascular endothelial growth factor receptor 3 (VEGFR-3) ameliorated aGVHD and

94 Vascular endothelial growth factor receptor 3 (VEGFR3) is an attractive 'lymp

95 adhesion molecule 1 and vascular endothelial growth factor receptor 3 (VEGFR3).

96 homeobox protein 1 and vascular endothelial growth factor receptor 3) as well as blood endothelial m

97 , we have shown that the RTK human epidermal growth factor receptor 4 (Her4, also known as Erbb4) can

98 eptor activation loop (from platelet-derived growth factor receptor, a receptor tyrosine kinase) and

99 Although oncogenic drivers such as epidermal growth factor receptor activation and Phosphatase and Te

100 MAN2A1-FER in 4 cell lines led to epidermal growth factor receptor activation of BRAF, MEK, and AKT;

101 such components as immune system receptors, growth factor receptors, adhesion, and cell-to-cell cont

102 Their role as growth factor receptors, along with other characteristic

103 ociation with TP53 loss and platelet-derived growth factor receptor alpha (PDGFRA) amplification.

104 show an essential role for platelet-derived growth factor receptor alpha (Pdgfra) in directing cardi

105 r tyrosine kinase (KIT) and platelet-derived growth factor receptor alpha (PDGFRA) mutations.

106 , tyrosine kinase 2 (TYK2), platelet-derived growth factor receptor alpha (PDGFRA), and fibroblast gr

107 Here, we show that platelet-derived growth factor receptor alpha (PDGFRalpha) and its ligand

108 and exhibit an increase in platelet-derived growth factor receptor alpha (PDGFRalpha) and laminin be

109 Here we report that platelet-derived growth factor receptor alpha (PDGFRalpha) positive ( + )

110 In this study, we isolated Platelet-derived growth factor receptor alpha (PDGFRalpha) positive proge

111 gnaling pathways, including platelet-derived growth factor receptor alpha (PDGFRalpha) signaling, whi

112 Platelet-derived growth factor receptor alpha (PDGFRalpha), a tyrosine ki

113 new myelin by fate mapping platelet-derived growth factor receptor alpha (PDGFRalpha), Olig2+, and P

114 ng nonmuscle myosin II- and platelet-derived growth factor receptor alpha-mediated contractility and

115 usor excitability involving platelet-derived growth factor receptor-alpha positive (PDGFRalpha(+)) in

116 itutively activated PDGFRA (platelet-derived growth factor receptor-alpha) under control of the sox10

117 (RTKs) such as PDGFRalpha (platelet-derived growth factor receptor-alpha), which show frequent aberr

118 as conditionally blocked in platelet-derived growth factor receptor-alpha-positive adipose progenitor

119 tissue progenitor cells, 3) platelet-derived growth factor receptor-alpha-positive cells, 4) alpha-sm

120 ve tissue progenitor cells, platelet-derived growth factor receptor-alpha-positive cells, and alpha-s

121 se and mitogenic content including epidermal growth factor receptor and c-Src.

122 asis suppressor interacts with the epidermal growth factor receptor and mediates its downstream signa

123 ized SHP2 co-localizes with platelet-derived growth factor receptor and NOX1/4.

124 r peptides relevant to cancer from epidermal growth factor receptor and telomerase.

125 Many receptor systems, notably including growth factor receptors and G protein-coupled receptors,

126 ivity is stimulated by diverse oncogenes and growth factor receptors, and elevated PI3K signaling is

127 lastic microspheres and vascular endothelial growth factor receptor antagonist in polystyrene microsp

128 ellular vesicle instead displaying epidermal growth-factor receptor aptamer inhibited orthotopic brea

129 d-type FER, and phosphorylated the epidermal growth factor receptor at tyrosine 88 in its N-terminus.

130 h revealed up-regulation of platelet-derived growth factor receptor beta (Pdgfrb) and insulin-like gr

131 inib targets including Abl, platelet derived growth factor receptor beta (PDGFRbeta) and the collagen

132 esenchymal cells expressing platelet-derived growth factor receptor beta (PDGFRbeta) are known to be

133 Aberrant platelet-derived growth factor receptor beta (PDGFRbeta) signaling in can

134 mer specifically recognizes platelet-derived growth factor receptor beta and can cross the blood-brai

135 erve growth factor (b-NGF), platelet-derived growth factor receptor beta polypeptide (PDGFRb), bone m

136 e formation through Rabex-5/platelet-derived growth factor receptor-beta (PDGFRbeta)-mediated endocyt

137 crease in the expression of platelet-derived growth factor receptor-beta, a tyrosine kinase receptor

138 The molecular adapter growth factor receptor binding protein 14 (Grb14) is an

139 e combined treatment of vascular endothelial growth factor receptor blocker SU5416.

140 this occurs in vivo, we used the binding of growth factor receptor bound 2 (GRB2) to phosphorylated

141 r (EGFR) and the cytoplasmic adaptor protein growth factor receptor-bound protein 2 (Grb2) in a cellu

142 binding of the isolated SH2 domain of Grb2 (growth factor receptor-bound protein 2) and the isolated

143 Our previous studies have found that Growth factor receptor-bound protein 2-associated bindin

144 by expressing the nonlymphoid hematopoietic growth factor receptor c-MPL (myeloproliferative leukemi

145 ert RIBEs by acting through the insulin-like growth factor receptor DAF-2.

146 tional program, Np63 sustains the epithelial growth factor receptor (EGF-R) activation and the expres

147 ar testing of CRC tissues to guide epidermal growth factor receptor (EGFR) -targeted therapies and co

148 Inhibition of inflammation or epidermal growth factor receptor (EGFR) activity decreases fungal

149 on-independent manner by dampening Epidermal Growth Factor Receptor (EGFR) activity.

150 ot sufficient for response to anti-epidermal growth factor receptor (EGFR) agents in advanced colorec

151 cument that HCMV activation of the epidermal growth factor receptor (EGFR) and downstream phosphatidy

152 rough engagement and activation of epidermal growth factor receptor (EGFR) and integrins on the surfa

153 lls required the expression of the epidermal growth factor receptor (EGFR) and of its ligand, amphire

154 effector, the role of NDRG1 on the epidermal growth factor receptor (EGFR) and other members of the E

155 aracterize the interaction between epidermal growth factor receptor (EGFR) and the cytoplasmic adapto

156 slation of certain mRNAs including epidermal growth factor receptor (EGFR) and the Hippo pathway effe

157 In the model, epidermal growth factor receptor (EGFR) and vascular endothelial g

158 Mutations in K-Ras and epidermal growth factor receptor (EGFR) are mutually exclusive, bu

159 CKGROUND & AIMS: Inhibitors of the epidermal growth factor receptor (EGFR) are the first-line therapy

160 ant amplification and mutations of epidermal growth factor receptor (EGFR) are the most common oncoge

161 r bound 2 (GRB2) to phosphorylated epidermal growth factor receptor (EGFR) as a model system.

162 ract, we searched for modifiers of epidermal growth factor receptor (EGFR) dependency by performing C

163 Epidermal growth factor receptor (EGFR) family members play pivota

164 keratinocytes, where together with epidermal growth factor receptor (EGFR) forms a signaling complex

165 interaction is the removal of the epidermal growth factor receptor (EGFR) from the surface of the in

166 5, which results in the removal of epidermal growth factor receptor (EGFR) from the surface of the in

167 utations of exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene.

168 Epidermal growth factor receptor (EGFR) has been implicated in the

169 rent knowledge suggests a role for epidermal growth factor receptor (EGFR) in cholangiocyte specifica

170 te a well-established role for the epidermal growth factor receptor (EGFR) in tumorigenesis, EGFR act

171 The role of epidermal growth factor receptor (EGFR) inhibition in chemoradiati

172 ture predictive of response to the epidermal growth factor receptor (EGFR) inhibitor, erlotinib, in N

173 Reversible epidermal growth factor receptor (EGFR) inhibitors prompt a benefi

174 herapies, overcoming resistance to epidermal growth factor receptor (EGFR) inhibitors remains a major

175 Epidermal growth factor receptor (EGFR) interacts with integrins d

176 tin interaction for the sorting of epidermal growth factor receptor (EGFR) into ILVs for lysosomal de

177 ific targeting of oncogenic mutant epidermal growth factor receptor (EGFR) is a breakthrough in targe

178 The epidermal growth factor receptor (EGFR) is a clinically validated

179 The epidermal growth factor receptor (EGFR) is a prototypical receptor

180 The epidermal growth factor receptor (EGFR) is a receptor tyrosine kin

181 Epidermal growth factor receptor (EGFR) is central to epithelial c

182 demethylation and upregulation of epidermal growth factor receptor (EGFR) ligands amphiregulin (AREG

183 concurrent administration of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies with

184 ng cancer patients with activating epidermal growth factor receptor (EGFR) mutations typically benefi

185 lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations.

186 Here, using a beta-cell specific epidermal growth factor receptor (EGFR) null mouse, we show that e

187 ) of patients were found to harbor epidermal growth factor receptor (EGFR) or Kristen rat sarcoma vir

188 ferent data support a role for the epidermal growth factor receptor (EGFR) pathway during liver regen

189 cells had elevated ligand-induced epidermal growth factor receptor (EGFR) phosphorylation.

190 The epidermal growth factor receptor (EGFR) plays a critical role in n

191 xpression of amplified and mutated epidermal growth factor receptor (EGFR) presents a substantial cha

192 Epidermal growth factor receptor (EGFR) regulates many crucial cel

193 helial growth factor (VEGFR)-2 and epidermal growth factor receptor (EGFR) signaling by enhancing the

194 Epidermal growth factor receptor (EGFR) signaling has a critical r

195 Epidermal growth factor receptor (EGFR) signaling is a known media

196 Epidermal Growth Factor Receptor (EGFR) signaling is essential for

197 In addition, epidermal growth factor receptor (EGFR) signaling is regulated by

198 Aberrant epidermal growth factor receptor (EGFR) signaling is widespread in

199 Focusing on the epidermal growth factor receptor (EGFR) signaling network in HEK29

200 ls (FSCs) of the Drosophila ovary, Epidermal Growth Factor Receptor (EGFR) signaling promotes self-re

201 Despite decades of research in the epidermal growth factor receptor (EGFR) signalling field, and many

202 e to prevent ectopic expression of Epidermal growth factor receptor (EGFR) target genes.

203 -functional molecule comprising of epidermal growth factor receptor (EGFR) targeted nanobody (ENb) an

204 d solid tumor targets, such as the epidermal growth factor receptor (EGFR) that effectively induces c

205 Current anti-epidermal growth factor receptor (EGFR) therapy for oral cancer do

206 iously selected for binding to the epidermal growth factor receptor (EGFR) to create a bifunctional a

207 re, we find that LOX regulates the epidermal growth factor receptor (EGFR) to drive tumour progressio

208 progression-free survival with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor

209 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

210 0Met mutation after treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors

211 Here, we show that lnc-epidermal growth factor receptor (EGFR) upregulation in Tregs corr

212 Stimulation of the epidermal growth factor receptor (EGFR) with EGF, the beta2-adreno

213 chloride secretion, centred on the epidermal growth factor receptor (EGFr), are discussed.

214 repair pathway, controlled by the epidermal growth factor receptor (EGFR), is critical to recovery f

215 ng adenocarcinoma driven by mutant epidermal growth factor receptor (EGFR), mutant Kirsten rat sarcom

216 fit from therapies that target the epidermal growth factor receptor (EGFR), such as cetuximab.

217 ported to regulate the function of epidermal growth factor receptor (EGFR), the effect of protein met

218 ion lead to aberrant activation of epidermal growth factor receptor (EGFR), which subsequently activa

219 which was accompanied by enhanced epidermal growth factor receptor (EGFR)-mediated mitogenic signali

220 and leptomeningeal metastases-from epidermal growth factor receptor (EGFR)-mutant non-small-cell lung

221 , a well-characterized paradigm of epidermal growth factor receptor (EGFR)-Ras-ERK signaling, has ide

222 ole-brain radiotherapy (WBRT), and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors

223 encoding receptor tyrosine kinase epidermal growth factor receptor (EGFR).

224 n of the external (ecto) domain of Epidermal Growth Factor Receptor (EGFR).

225 ated that RCN2 interacted with the epidermal growth factor receptor (EGFR).

226 teraction of an engineered gD with epidermal growth factor receptor (EGFR).

227 nto siRNA carriers targeted to the epidermal growth factor receptor (EGFR).

228 The epidermal growth factor receptor (EGFR)/ErbB family of receptor ty

229 zole with or without lapatinib, an epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhib

230 gnaling by inhibiting formation of epidermal growth factor receptor (EGFR)/human epidermal growth fac

231 nase CK2 and the wild-type/mutated epidermal growth factor receptor (EGFR/EGFRvIII), which are overex

232 ells display slower trafficking of epidermal growth factor receptors (EGFR) from early to late endoso

233 tigen, PA) which was redirected to Epidermal Growth Factor Receptors (EGFR) or to human EGF receptors

234 ns, are barriers to effective anti-epidermal-growth-factor-receptor (EGFR) therapy.

235 eptor on these cells and vesicles (epidermal growth factor receptor, EGFR) reduces the intensity of t

236 blastoma cells expressing a mutant epidermal growth factor receptor (EGFRvIII) is responsible for the

237 can mediate signals via the human epidermal growth factor receptor (ErbB) tyrosine kinase family to

238 Signaling of growth factor receptor ERBB2 is critical for myocyte pro

239 specific protein 6, oncostatin M, hepatocyte growth factor receptor etc.

240 Members of the epidermal growth factor receptor family (ErbB family) possess a wi

241 lls resulted in a higher level of fibroblast growth factor receptor (FGFR) activation and ERK1/2 phos

242 The fibroblast growth factor receptor (FGFR) family of receptor tyrosin

243 stabilities of three full-length fibroblast growth factor receptor (FGFR) mutants harboring pathogen

244 mechanism of the kinase domain of Fibroblast Growth Factor Receptor (FGFR).

245 hetero-interactions between three fibroblast growth factor receptors-FGFR1, FGFR2, and FGFR3-in the a

246 Activation of the fibroblast growth factor receptor FGFR4 by FGF19 drives hepatocellu

247 harboring genetic alterations in fibroblast growth factor receptors (FGFRs) to determine the maximum

248 hemotherapy is beneficial in human epidermal growth factor receptor (HER) 1/HER2-positive metastatic

249 lonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking heregul

250 n the catalytically impaired human epidermal growth factor receptor (HER3/ERBB3) and its catalyticall

251 drenoceptor with dopamine, or the hepatocyte growth factor receptor (HGFR/c-MET) with an agonistic an

252 Further, epidermal growth factor receptor I (EGFR)-binding peptides are gen

253 horylation (on S2159) in response to certain growth factor receptors (i.e., EGF-receptor but not insu

254 Selective activation of epidermal growth factor receptor in renal proximal tubule induces

255 wth factor signaling by vascular endothelial growth factor receptor inhibition may complement antitum

256 to phosphoinositide 3-kinase and fibroblast growth factor receptor inhibition.

257 Purpuric drug eruptions caused by epidermal growth factor receptor inhibitors are uncommon and have

258 purpuric skin lesions after using epidermal growth factor receptor inhibitors from January 1, 2013,

259 antibiotic treatment; the doses of epidermal growth factor receptor inhibitors were also changed for

260 purpuric skin eruptions caused by epidermal growth factor receptor inhibitors.

261 een reported in patients receiving epidermal growth factor receptor inhibitors.

262 SOCS1 decreased the expression of epidermal growth factor receptor, Ins-Ralpha, and fibroblast growt

263 uired for efficient internalization of major growth factor receptors involved in liver regeneration a

264 inase inhibitor crizotinib and the epidermal growth factor receptor kinase inhibitor canertinib; thes

265 The tyrosine kinase mast/stem cell growth factor receptor KIT is an example of a clinically

266 The growth factor receptor Kit is involved in hematopoietic

267 tion by forming a complex with the epidermal growth factor receptor, leading to activation of the ERK

268 Following gut epithelial damage, epidermal growth factor receptor/mitogen-activated protein kinase

269 NSCLC) patients with an activating epidermal growth factor receptor mutation who were treated with ge

270 eral expression of the apically sorted nerve growth factor receptor (NGFR, p75; extracellular and tra

271 3K-dependent kinase AKT following binding of growth factor receptors or Toll-like receptor 4.

272 Eps15 (epidermal growth factor receptor pathway substrate 15)-homology do

273 Platelet-derived growth factor receptor (PDGFR) senses extracellular grow

274 ed ALL proliferation in ABL/platelet-derived growth factor receptor (PDGFR)-mutant models with mean 6

275 ein-1 prevented 20-HETE-mediated endothelial growth factor receptor phosphorylation and angiotensin-c

276 ection of spermatogonial mutations affecting growth factor receptor-RAS signaling, highlight its prev

277 Inhibition of the epidermal growth factor receptor represents one of the most promis

278 mote focal adhesion formation and potentiate growth factor receptor signaling through kinase.

279 and incorporation into glutathione, linking growth factor receptor signaling with amino acid uptake

280 They regulate epidermal growth factor receptor signalling in Drosophila by relea

281 rotein cortactin downstream of the epidermal growth factor receptor-Src-Arg kinase cascade is known t

282 te acetate, Gq/11-coupled GPCR, or epidermal growth factor receptor stimulation promotes beta-arresti

283 lect patients who may benefit from epidermal growth factor receptor-targeted therapy in non-small cel

284 iate the increase independently of epidermal growth factor receptor transactivation.

285 roperties via mechanisms involving the nerve growth factor receptors (tropomyosin-related kinase A [T

286 EA was previously shown to bind to the nerve growth factor receptor, tropomyosin-related kinase A (Tr

287 tor (in 54,115 patients) and human epidermal growth factor receptor type 2 (HER2) (in 15,418 patients

288 tudies demonstrated that the human epidermal growth factor receptor type 2 (HER2)-targeting ADAPT6 la

289 able inhibitory percentage against Epidermal Growth Factor Receptor tyrosine kinase (EGFR-TK), in in-

290 The epidermal growth factor receptor tyrosine kinase inhibitor erlotin

291 sease progression after first-line epidermal growth factor receptor tyrosine kinase inhibitor therapy

292 Epidermal growth factor receptor tyrosine kinase inhibitors, inclu

293 hangiogenesis involving vascular endothelial growth factor-receptor tyrosine kinase and TGF-beta and

294 Angiogenesis, in which vascular endothelial growth factor receptor (VEGFR) 2 plays an essential role

295 se inhibitors targeting vascular endothelial growth factor receptor (VEGFR) and approved for radioiod

296 CAM-1, VE-cadherin, and vascular endothelial growth factor receptors (VEGFRs) that resides at endothe

297 fferentiation, the transition from epidermal growth factor receptor(+) villous cytotrophoblasts into

298 of IPT/TIG domains of plexins and hepatocyte growth factor receptor was not affected in TMTC KO cells

299 agments F(ab')2 and Fab) targeting epidermal growth factor receptor were labeled with Alexa750 or (64

300 +) pancreata leads to reduction of epidermal growth factor receptor, which is critical for ADM initia